Literature DB >> 22304432

Fibroblast growth factor-2-induced cardioprotection against myocardial infarction occurs via the interplay between nitric oxide, protein kinase signaling, and ATP-sensitive potassium channels.

Janet R Manning1, Gregory Carpenter, Darius R Porter, Stacey L House, Daniel A Pietras, Thomas Doetschman, Jo el J Schultz.   

Abstract

Fibroblast growth factor-2 (FGF2) protects the heart from ischemia-reperfusion (I-R) injury via a vast network of protein kinases. In the heart, downstream effectors of these FGF2-triggered signals have not yet been identified. It is hypothesized that nitric oxide (NO) signaling and ATP-sensitive potassium (K(ATP)) channel activity are key effectors of protein kinases activated by FGF2-mediated cardioprotection. Hearts with a cardiac-specific overexpression of FGF2 (FGF2 Tg) were subjected to I-R injury in the absence or the presence of selective inhibitors of NO synthase (NOS) isoforms or sarcolemmal (sarcK(ATP)) and mitochondrial (mitoK(ATP)) K(ATP) channels. Multiple NOS isoforms are necessary for FGF2-mediated cardioprotection, and nitrite levels are significantly reduced in FGF2 Tg hearts upon inhibition of protein kinase C or mitogen-activated protein kinases. Likewise, sarcK(ATP) and mitoK(ATP) channels are important for cardioprotection elicited by endogenous FGF2. These findings suggest that FGF2-induced cardioprotection occurs via protein kinase-NOS pathways as well as K(ATP) channel activity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22304432      PMCID: PMC7041406          DOI: 10.3109/08977194.2012.656759

Source DB:  PubMed          Journal:  Growth Factors        ISSN: 0897-7194            Impact factor:   2.511


  95 in total

Review 1.  Molecular and cellular mechanisms of myocardial stunning.

Authors:  R Bolli; E Marbán
Journal:  Physiol Rev       Date:  1999-04       Impact factor: 37.312

2.  nNOS gene deletion exacerbates pathological left ventricular remodeling and functional deterioration after myocardial infarction.

Authors:  Dana Dawson; Craig A Lygate; Mei-Hua Zhang; Karen Hulbert; Stefan Neubauer; Barbara Casadei
Journal:  Circulation       Date:  2005-12-13       Impact factor: 29.690

Review 3.  The ubiquitous role of nitric oxide in cardioprotection.

Authors:  Steven P Jones; Roberto Bolli
Journal:  J Mol Cell Cardiol       Date:  2005-11-08       Impact factor: 5.000

4.  Smaller infarct after preconditioning does not predict extent of early functional improvement of reperfused heart.

Authors:  M V Cohen; X M Yang; J M Downey
Journal:  Am J Physiol       Date:  1999-11

5.  Cardioprotective PKG-independent NO signaling at reperfusion.

Authors:  Michael V Cohen; Xi-Ming Yang; Yanping Liu; Nataliya V Solenkova; James M Downey
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-09-17       Impact factor: 4.733

6.  Effects of cardioselective KATP channel antagonism on basal, stimulated, and ischaemic myocardial function in in vivo failing canine heart.

Authors:  Walter F Saavedra; Nazareno Paolocci; David A Kass
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

7.  ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice.

Authors:  Anindita Das; Fadi N Salloum; Lei Xi; Yuan J Rao; Rakesh C Kukreja
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-03-13       Impact factor: 4.733

8.  Bidirectional regulation of neuronal nitric-oxide synthase phosphorylation at serine 847 by the N-methyl-D-aspartate receptor.

Authors:  Gerald A Rameau; Ling-Yu Chiu; Edward B Ziff
Journal:  J Biol Chem       Date:  2004-01-13       Impact factor: 5.157

9.  Integrated pharmacological preconditioning in combination with adenosine, a mitochondrial KATP channel opener and a nitric oxide donor.

Authors:  Yuka Uchiyama; Hajime Otani; Takayuki Okada; Takamichi Uchiyama; Hideki Ninomiya; Masakuni Kido; Hiroji Imamura; Shinichi Nakao; Koh Shingu
Journal:  J Thorac Cardiovasc Surg       Date:  2003-07       Impact factor: 5.209

Review 10.  Biological activities of fibroblast growth factor-2 in the adult myocardium.

Authors:  Karen A Detillieux; Farah Sheikh; Elissavet Kardami; Peter A Cattini
Journal:  Cardiovasc Res       Date:  2003-01       Impact factor: 10.787

View more
  5 in total

1.  Quantitative phosphoproteomics using acetone-based peptide labeling: method evaluation and application to a cardiac ischemia/reperfusion model.

Authors:  Aruna B Wijeratne; Janet R Manning; Jo El J Schultz; Kenneth D Greis
Journal:  J Proteome Res       Date:  2013-09-24       Impact factor: 4.466

2.  Multivalent conjugates of basic fibroblast growth factor enhance in vitro proliferation and migration of endothelial cells.

Authors:  Aline Zbinden; Shane Browne; Eda I Altiok; Felicia L Svedlund; Wesley M Jackson; Kevin E Healy
Journal:  Biomater Sci       Date:  2018-05-01       Impact factor: 6.843

3.  PI3K/Akt/FoxO3a signaling mediates cardioprotection of FGF-2 against hydrogen peroxide-induced apoptosis in H9c2 cells.

Authors:  Mi-Hua Liu; Guo-Hua Li; Li-Jun Peng; Shun-Lin Qu; Yuan Zhang; Juan Peng; Xin-Yuan Luo; Heng-Jing Hu; Zhong Ren; Yao Liu; Hui Tang; Lu-Shan Liu; Zhi-Han Tang; Zhi-Sheng Jiang
Journal:  Mol Cell Biochem       Date:  2016-02-22       Impact factor: 3.396

4.  Fibroblast growth factor 2 is an essential cardioprotective factor in a closed-chest model of cardiac ischemia-reperfusion injury.

Authors:  Stacey L House; Joy Wang; Angela M Castro; Carla Weinheimer; Attila Kovacs; David M Ornitz
Journal:  Physiol Rep       Date:  2015-01-27

5.  Phosphoproteomic analysis identifies phospho-Threonine-17 site of phospholamban important in low molecular weight isoform of fibroblast growth factor 2-induced protection against post-ischemic cardiac dysfunction.

Authors:  Janet R Manning; Aruna B Wijeratne; Brian B Oloizia; Yu Zhang; Kenneth D Greis; Jo El J Schultz
Journal:  J Mol Cell Cardiol       Date:  2020-08-25       Impact factor: 5.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.